RZLT - NASDAQ

Rezolute, Inc.

Rezolute, Inc.

RZLTยทNASDAQ

$4.58

+14%
HealthcareBiotechnology

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$441.02M
EPS-0.9800
P/E Ratio-4.67
Earnings Date09/10/2026
Rezolute, Inc.

Rezolute, Inc. Fair Value Envelope

RZLT ยท NASDAQ

Our analysis suggests that RZLT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.58, this represents a potential HIDDEN relative to our calculated worth for Rezolute, Inc..

HIDDEN
Intrinsic Value
Current Price: $4.58

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$184.4M
+ Cash & Equivalents$94.1M
Firm Value-$90.3M
- Debt$1.6M
Equity Value-$91.9M
/ Shares Outstanding92,727,500B
DCF Value-$1
OVERVALUED BY 122%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$55.0M
-$43.8M
-$34.8M
-$27.7M
-$22.1M
-$17.6M
-$14.0M
-$11.1M
-$8.9M
-$7.0M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$55.0M
-$43.8M
-$34.8M
-$27.7M
-$22.1M
-$17.6M
-$14.0M
-$11.1M
-$8.9M
-$7.0M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$50.9M
-$37.5M
-$27.6M
-$20.4M
-$15.0M
-$11.1M
-$8.2M
-$6.0M
-$4.4M
-$3.3M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your RZLT research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.